NO20045043L - Pyrimidinonforbindelser, sammensetninger og fremgangsmater - Google Patents
Pyrimidinonforbindelser, sammensetninger og fremgangsmaterInfo
- Publication number
- NO20045043L NO20045043L NO20045043A NO20045043A NO20045043L NO 20045043 L NO20045043 L NO 20045043L NO 20045043 A NO20045043 A NO 20045043A NO 20045043 A NO20045043 A NO 20045043A NO 20045043 L NO20045043 L NO 20045043L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- methods
- pyrimidinone compounds
- compounds
- pyrimidinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forbindelser anvendelige for behandling av cellulære proliferative sykdommer og lidelser ved å modulere aktiviteten til KSP er beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37965802P | 2002-05-09 | 2002-05-09 | |
PCT/US2003/013627 WO2003094839A2 (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20045043L true NO20045043L (no) | 2005-02-08 |
Family
ID=29420548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20045043A NO20045043L (no) | 2002-05-09 | 2004-11-19 | Pyrimidinonforbindelser, sammensetninger og fremgangsmater |
Country Status (20)
Country | Link |
---|---|
US (2) | US7166595B2 (no) |
EP (1) | EP1503993A4 (no) |
JP (1) | JP2006508030A (no) |
KR (1) | KR20050036911A (no) |
CN (1) | CN100491358C (no) |
AR (1) | AR039985A1 (no) |
AU (1) | AU2003223786A1 (no) |
BR (1) | BR0309892A2 (no) |
CA (1) | CA2485148A1 (no) |
IL (2) | IL165046A0 (no) |
IS (1) | IS7520A (no) |
MX (1) | MXPA04011074A (no) |
MY (1) | MY140767A (no) |
NO (1) | NO20045043L (no) |
NZ (1) | NZ537076A (no) |
PL (1) | PL373412A1 (no) |
RU (1) | RU2004135554A (no) |
TW (1) | TW200406387A (no) |
WO (1) | WO2003094839A2 (no) |
ZA (1) | ZA200409881B (no) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
DE60231439D1 (de) * | 2001-12-06 | 2009-04-16 | Merck & Co Inc | Mitotische kinesinhemmer |
US7009049B2 (en) * | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
EP1553931A4 (en) * | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
EP1503993A4 (en) | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | COMPOUNDS, METHODS AND COMPOSITIONS |
JP2005536475A (ja) * | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
EP1509507A4 (en) * | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESIN |
JP2005538062A (ja) * | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
WO2004009036A2 (en) * | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US7557115B2 (en) * | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
KR20050107784A (ko) * | 2003-03-07 | 2005-11-15 | 아스트라제네카 아베 | 신규한 융합 복소환 및 이의 용도 |
AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
EP1682534A2 (en) * | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
EP1680420A4 (en) * | 2003-11-07 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US7439254B2 (en) * | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CA2547209A1 (en) | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CN1938281A (zh) * | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
BRPI0509653A (pt) * | 2004-04-06 | 2007-10-09 | Chiron Corp | inibidores cinesina mitótica |
MXPA06011958A (es) | 2004-05-21 | 2006-12-15 | Chiron Corp | Derivados de quinolina sustituidos como inhibidores de cinesina mitotica. |
US7576221B2 (en) | 2004-06-18 | 2009-08-18 | Novartis Vaccines And Diagnostics, Inc. | Substituted imidazole derivatives |
US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
US7375102B2 (en) * | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
JP2008506759A (ja) * | 2004-07-22 | 2008-03-06 | アストラゼネカ アクチボラグ | 癌の処置および予防に有用な縮合ピリミドン類 |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
MX2007001953A (es) | 2004-08-18 | 2007-05-09 | Astrazeneca Ab | Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer. |
JP2008517057A (ja) | 2004-10-19 | 2008-05-22 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | インドールおよびベンゾイミダゾール誘導体 |
US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
TW200716102A (en) * | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
CN101558049B (zh) | 2006-11-13 | 2012-08-15 | 诺瓦提斯公司 | 作为ksp抑制剂的被取代的吡唑和***化合物 |
CN101622247A (zh) | 2007-01-05 | 2010-01-06 | 诺瓦提斯公司 | 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物 |
EP2070932A1 (en) * | 2007-12-13 | 2009-06-17 | 4Sc Ag | Pyrazolotriazines |
WO2011001115A1 (fr) * | 2009-07-02 | 2011-01-06 | Sanofi-Aventis | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb ) |
DK2542084T3 (en) * | 2010-03-04 | 2018-03-26 | Merck Sharp & Dohme | CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND THEIR USE IN TREATMENT OF PSYCHOTIC DISORDERS |
BR112012030633A2 (pt) * | 2010-05-31 | 2016-08-16 | Council Scient Ind Res | agentes antituberculosos |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
JP6454348B2 (ja) | 2013-12-19 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体およびその医薬品への応用 |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2649141C2 (ru) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
JP6837482B2 (ja) | 2015-10-14 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド |
MX2018007155A (es) | 2015-12-16 | 2018-08-15 | Squibb Bristol Myers Co | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
KR102433280B1 (ko) | 2016-03-24 | 2022-08-17 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 6-히드록시-4-옥소-1,4-디히드로피리미딘-5-카르복스아미드 |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20210380538A1 (en) * | 2018-11-01 | 2021-12-09 | Ahammune Biosciences Private Limited | Novel imidazole compounds, process for the synthesis and uses thereof |
CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
CN113897631B (zh) * | 2021-10-24 | 2023-05-09 | 昆明学院 | 电化学合成吡啶-2-酮衍生物的方法 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (no) | 1963-05-18 | |||
US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
BG16042A3 (bg) | 1968-11-12 | 1972-05-20 | Nans Ott | Метод за получаване на нови 2(1н)-хиназолинони |
US3962244A (en) | 1971-01-23 | 1976-06-08 | Hoechst Aktiengesellschaft | Benzene sulfonyl ureas |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
US4011324A (en) | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
DE2747357A1 (de) * | 1977-10-21 | 1979-04-26 | Bayer Ag | Substituierte pyrimidinyl(thiono) (thiol)phosphor (phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
US4281127A (en) | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
EP0278530A3 (de) | 1980-08-30 | 1989-08-02 | Hoechst Aktiengesellschaft | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung |
JPS5821669A (ja) * | 1981-07-30 | 1983-02-08 | Tetsuzo Kato | 2−(1−アシルアミノアルキル)−6−メチル−4(3h)−ピリミジノンの製法 |
JPS6019789A (ja) | 1983-07-12 | 1985-01-31 | Kyorin Pharmaceut Co Ltd | イミダゾ〔1,5−a〕ピリミジン誘導体 |
JPS6143191A (ja) * | 1984-08-07 | 1986-03-01 | Kyorin Pharmaceut Co Ltd | イミダゾ〔1,5−a〕ピリミジン誘導体 |
GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
GB8530144D0 (en) * | 1985-12-06 | 1986-01-15 | Fujisawa Pharmaceutical Co | Imidazo(1,5-a)heterocyclic compounds |
DE3609598A1 (de) | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US5187167A (en) | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
US4729996A (en) | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
GB8707053D0 (en) | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
US4866084A (en) | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
US4808590A (en) | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4857530A (en) | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
GB8827820D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
GB8827988D0 (en) | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
GB8829296D0 (en) * | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
US4970226A (en) | 1989-10-03 | 1990-11-13 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents |
US5264439A (en) | 1990-02-13 | 1993-11-23 | Merck & Co., Inc. | Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element |
ZA913730B (en) | 1990-05-30 | 1992-02-26 | Ici Plc | Anti-tumor compounds |
FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
JPH04147134A (ja) * | 1990-10-09 | 1992-05-20 | Konica Corp | 新規な写真用カプラー |
JPH04147135A (ja) * | 1990-10-10 | 1992-05-20 | Konica Corp | 新規な写真用カプラー |
GB9105771D0 (en) | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
JPH0649070A (ja) * | 1991-07-23 | 1994-02-22 | Kyorin Pharmaceut Co Ltd | イミダゾ[1,5−a]ピリミジン誘導体 |
US5316906A (en) | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9205907D0 (en) | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
US5430148A (en) | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
US5817662A (en) | 1992-11-09 | 1998-10-06 | Cell Therapeutics, Inc. | Substituted amino alkyl compounds |
US5804584A (en) | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
AU6087894A (en) | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
WO1994016704A1 (en) | 1993-01-19 | 1994-08-04 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
US5574057A (en) | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
US5837703A (en) | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
US5342944A (en) | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
EP0724573A1 (en) * | 1993-10-20 | 1996-08-07 | PHARMACIA & UPJOHN COMPANY | Pyrimidinones as antiarthritic and anti-inflammatories |
US20020198326A1 (en) | 1993-11-12 | 2002-12-26 | Taizo Aoyama | Polyolefin resin composition |
CA2113229C (en) | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
CA2192470A1 (en) | 1994-01-14 | 1995-07-20 | Paul A. Brown | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
EP0746557A4 (en) | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | INTRACELLULAR SIGNALING MEDIATORS |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
DE4413169C1 (de) * | 1994-04-15 | 1995-05-11 | Daimler Benz Ag | Schaltvorrichtung für ein Zahnräderwechselgetriebe |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
JPH09165385A (ja) | 1994-08-26 | 1997-06-24 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
US5891879A (en) | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
US6245768B1 (en) | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5922866A (en) | 1995-08-30 | 1999-07-13 | Otsuka Pharmaceutical Factory, Inc. | Process for preparing quinazolin-4-one derivatives |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
DE19546918A1 (de) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
US5852024A (en) | 1997-02-11 | 1998-12-22 | Hadasit | Treatment and prevention of adhesions |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
AU2107199A (en) | 1998-01-08 | 1999-07-26 | Regents Of The University Of California, The | Kinesin motor modulators derived from the marine sponge (adocia) |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
AU7080500A (en) | 1999-08-27 | 2001-03-26 | Chemocentryx, Inc. | Compounds and methods for modulating cxcr3 function |
US6156758A (en) | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
BRPI0014526C1 (pt) * | 1999-09-16 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo |
WO2001019800A2 (en) * | 1999-09-16 | 2001-03-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1226129B1 (en) * | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
US6380205B1 (en) | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
EP1259234B9 (en) * | 1999-12-30 | 2007-02-14 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
WO2001081346A2 (en) * | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
EP1307201B1 (de) | 2000-08-01 | 2004-11-24 | Bayer HealthCare AG | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1387674B1 (en) * | 2000-10-13 | 2017-01-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
EA007538B1 (ru) * | 2000-12-11 | 2006-10-27 | Туларик Инк. | Антагонисты cxcr3 |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
JP4178816B2 (ja) * | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 医薬組成物 |
US7081460B2 (en) | 2001-04-09 | 2006-07-25 | Ortho-Mcneil Pharmaceutical, Inc. | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
US7365199B2 (en) | 2001-04-20 | 2008-04-29 | Fujifilm Corporation | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
US20030144350A1 (en) | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
EP1434584A2 (en) | 2001-09-05 | 2004-07-07 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
EP2116248A1 (en) * | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
US7169780B2 (en) * | 2001-10-26 | 2007-01-30 | Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
EP1441734B1 (en) | 2001-10-26 | 2007-02-28 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
AU2002366103A1 (en) * | 2001-11-19 | 2003-06-10 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
US6753428B2 (en) * | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
JP4464136B2 (ja) | 2001-12-06 | 2010-05-19 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸***キネシン阻害薬 |
JP4597519B2 (ja) | 2001-12-06 | 2010-12-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸***キネシン阻害薬 |
JP2005515208A (ja) | 2001-12-06 | 2005-05-26 | メルク エンド カムパニー インコーポレーテッド | 有糸***性キネシン阻害剤 |
DE60231439D1 (de) * | 2001-12-06 | 2009-04-16 | Merck & Co Inc | Mitotische kinesinhemmer |
WO2003049679A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
US7009049B2 (en) * | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
AU2003228283A1 (en) * | 2002-03-07 | 2003-09-22 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
EP1553931A4 (en) * | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
EP1503993A4 (en) | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | COMPOUNDS, METHODS AND COMPOSITIONS |
EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESIN |
JP2005536475A (ja) * | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
EP1517904A4 (en) | 2002-05-23 | 2007-02-21 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESIN |
JP2005538062A (ja) * | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
US20040092561A1 (en) * | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
WO2004009036A2 (en) * | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
EP1594849A4 (en) | 2003-01-17 | 2007-07-04 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
KR20050107784A (ko) | 2003-03-07 | 2005-11-15 | 아스트라제네카 아베 | 신규한 융합 복소환 및 이의 용도 |
US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
EP1682534A2 (en) * | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
-
2003
- 2003-05-02 EP EP03719989A patent/EP1503993A4/en not_active Withdrawn
- 2003-05-02 CA CA002485148A patent/CA2485148A1/en not_active Abandoned
- 2003-05-02 MX MXPA04011074A patent/MXPA04011074A/es active IP Right Grant
- 2003-05-02 CN CNB03816177XA patent/CN100491358C/zh not_active Expired - Fee Related
- 2003-05-02 PL PL03373412A patent/PL373412A1/xx unknown
- 2003-05-02 WO PCT/US2003/013627 patent/WO2003094839A2/en active Application Filing
- 2003-05-02 KR KR1020047018077A patent/KR20050036911A/ko not_active Application Discontinuation
- 2003-05-02 BR BRPI0309892-3A patent/BR0309892A2/pt not_active IP Right Cessation
- 2003-05-02 US US10/429,195 patent/US7166595B2/en not_active Expired - Fee Related
- 2003-05-02 AU AU2003223786A patent/AU2003223786A1/en not_active Abandoned
- 2003-05-02 RU RU2004135554/04A patent/RU2004135554A/ru unknown
- 2003-05-02 JP JP2004502928A patent/JP2006508030A/ja active Pending
- 2003-05-02 NZ NZ537076A patent/NZ537076A/en unknown
- 2003-05-07 MY MYPI20031725A patent/MY140767A/en unknown
- 2003-05-07 TW TW092112382A patent/TW200406387A/zh unknown
- 2003-05-08 AR ARP030101617A patent/AR039985A1/es unknown
-
2004
- 2004-11-03 IS IS7520A patent/IS7520A/is unknown
- 2004-11-04 IL IL16504604A patent/IL165046A0/xx unknown
- 2004-11-19 NO NO20045043A patent/NO20045043L/no not_active Application Discontinuation
- 2004-12-07 ZA ZA200409881A patent/ZA200409881B/en unknown
-
2006
- 2006-11-15 US US11/600,683 patent/US7482343B2/en not_active Expired - Fee Related
-
2007
- 2007-11-20 IL IL187528A patent/IL187528A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2004135554A (ru) | 2006-01-20 |
PL373412A1 (en) | 2005-08-22 |
CN100491358C (zh) | 2009-05-27 |
EP1503993A4 (en) | 2006-05-03 |
US7482343B2 (en) | 2009-01-27 |
WO2003094839A3 (en) | 2004-09-16 |
WO2003094839A2 (en) | 2003-11-20 |
IS7520A (is) | 2004-11-03 |
TW200406387A (en) | 2004-05-01 |
BR0309892A2 (pt) | 2011-04-05 |
IL165046A0 (en) | 2005-12-18 |
NZ537076A (en) | 2007-06-29 |
IL187528A0 (en) | 2008-03-20 |
WO2003094839A8 (en) | 2004-06-24 |
AU2003223786A1 (en) | 2003-11-11 |
US7166595B2 (en) | 2007-01-23 |
US20040077662A1 (en) | 2004-04-22 |
CA2485148A1 (en) | 2003-11-20 |
MXPA04011074A (es) | 2005-06-08 |
US20070135432A1 (en) | 2007-06-14 |
KR20050036911A (ko) | 2005-04-20 |
EP1503993A2 (en) | 2005-02-09 |
MY140767A (en) | 2010-01-15 |
AR039985A1 (es) | 2005-03-09 |
JP2006508030A (ja) | 2006-03-09 |
ZA200409881B (en) | 2006-04-26 |
CN1665788A (zh) | 2005-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20045043L (no) | Pyrimidinonforbindelser, sammensetninger og fremgangsmater | |
WO2003103575A3 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
WO2004018058A3 (en) | Compounds, compositions, and methods | |
NO20052267L (no) | Forbindelser, Preparater og Metoder | |
MY140169A (en) | Compounds, compositions, and methods | |
MXPA06012796A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
WO2006113432A3 (en) | Compounds, compositions and methods | |
WO2004009036A3 (en) | Compounds compositions and methods | |
WO2007056469A3 (en) | Certain chemical entities, compositions, and methods | |
WO2007056143A3 (en) | Certain chemical entities, compositions, and methods | |
MY169308A (en) | Treatment of tnf? related disorders | |
WO2007056078A3 (en) | Certain chemical entities, compositions, and methods | |
AU2003252025A8 (en) | Compounds, compositions, and methods | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
WO2004034972A3 (en) | Compounds, compositions, and methods | |
WO2005046588A3 (en) | Compounds, compositions, and methods | |
WO2004064741A3 (en) | Compounds, compositions, and methods | |
WO2005042697A3 (en) | Compounds, compositions and methods | |
WO2004100873A3 (en) | Compounds, compositions, and methods | |
DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
WO2004024086A3 (en) | Compounds, compositions and methods | |
WO2004032879A3 (en) | Compounds, compositions, and methods | |
WO2005062847A3 (en) | Compounds, compositions and methods | |
WO2005041888A3 (en) | Pyrimidin-4-one compounds, compositions and methods | |
WO2004103282A3 (en) | Compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |